The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology.

1. Bacterial Partnering Terms and Agreements
The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and
unprecedented access to the bacterial partnering deals and agreements entered into by the worlds
leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter bacterial
partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains
a right or an option right to license the licensors bacterial technology. These deals tend to be
multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into
the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst
many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms
of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual bacterial deals and contract documents as
submitted to the Securities Exchange Commission by companies and their partners. Contract documents
provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each party’s ability to derive value from
the deal.
The initial chapters of this report provide an orientation of bacterial dealmaking and business activities.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in bacterial dealmaking since 2007 covering trends by year,
deal type, stage of development, technology type and therapeutic indication. In addition the chapter
includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment,
milestone payments and royalty rates. Analysis includes median values and distribution of values for each
stage of development.
Chapter 3 provides a review of the leading bacterial deals since 2007. Deals are listed by headline value,
signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the
deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary
followed by a comprehensive listing of bacterial deals, as well as contract documents available in the
public domain. Where available, each deal title links via Weblink to an online version of the actual
contract document, providing easy access to each contract document on demand.
Chapter 5 provides comprehensive access to all bacterial deals since 2007 where a deal contract is
available, providing the user with direct access to contracts as filed with the SEC regulatory authorities.
Each deal title links via Weblink to an online version of the deal record contract document, providing easy
access to each contract document on demand.

2. Chapter 6 provides a comprehensive directory of all bacterial partnering deals signed and announced
since 2007. The chapter is organized by specific infectives therapy focus. Each deal title links via Weblink
to an online version of the deal record and where available, the contract document, providing easy access
to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all bacterial partnering deals signed
and announced since 2007. The appendices are organized by company A-Z, stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title
links via Weblink to an online version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in bacterial
partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in
the research, development and commercialization of bacterial technologies and products.
Buy your copy of this report @ http://www.reportsnreports.com/reports/175339-bacterial-
partnering-terms-and-agreements.html
Major points covered in Table of Contents of this report include:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in bacterial dealmaking
Chapter 3 – Leading bacterial deals
Chapter 4 – Bigpharma bacterial deals
Chapter 5 – Bacterial partnering contracts directory
Chapter 6 – Bacterial dealmaking by indication
Chapter 7 – Partnering resource center
Table of Figures

3. Browse reports related to Boitechnology @
http://www.reportsnreports.com/market-research/biotechnology/
Report Details:
Published: July 2012
No. of Pages: 801
Price: Single User License – US$1995 Corporate User License – US$2995
Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@reportsandreports.com
Connect With Us: